Rodman and Renshaw Starts Callisto Pharmaceuticals (KAL) at Outperform
KAL Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Rodman and Renshaw initiates Callisto Pharmaceuticals (AMEX: KAL) with an Outperform and a $3 price target.
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Goldman Sachs Cuts Numbers on Tiffany & Co. (TIF) after Weak Q1, Guidance
- Goldman Sachs Boosts Numbers on PVH Corp (PVH) After Q1 Beat
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
